Rhizen Pharmaceuticals develops next generation medicines targeting cancer and inflammation, with ongoing clinical studies for their products.

Rhizen Pharmaceuticals

Summit Therapeutics is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of medicinal therapies intended to improve quality of life and resolve serious unmet medical needs, self-described.

Summit Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

TG Therapeutics, Inc.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).

Hercules Capital

#Milestones – TG Therapeutics announced preliminary 4th quarter and full year 2023 net BRIUMVI revenue (unaudited), as well as our anticipated development milestones for 2024! Read the press release here: bit.ly/4aNu3nd #FearlessForPatients #TGTX #Strategy2024

#DontMissIt – TG CEO Mike Weiss will be presenting at the 42nd Annual J.P.Morgan Healthcare Conference in 15 minutes! Live Webcast at: https://lnkd.in/eguXMYM #JPM24 #FearlessForPatients #TGTX

#DontMissIt – TG CEO Mike Weiss will be presenting today at the 42nd Annual J.P.Morgan Healthcare Conference - Tues, Jan. 9th @ 4:30PM PT/7:30PM ET. Live Webcast at: https://lnkd.in/eguXMYM #JPM24 #FearlessForPatients #TGTX

#Breaking - Just announced a Global License Agreement with Precision BioSciences for the Development & Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases. Details: bit.ly/3vzHEhG #FearlessForPatients #TGTX

#SaveTheDate - TG CEO Mike Weiss will present at the 42nd Annual J.P.Morgan Healthcare Conference next week. Live webcast Tues, Jan. 9th @ 4:30PM PT/7:30PM ET. Details: bit.ly/47qzxS7 webcast at: https://lnkd.in/eguXMYM #JPM24 #FearlessForPatients #TGTX

The team at TG Therapeutics wishes you and your family a very happy and healthy holiday season! #TGTX #FearlessForPatients

#Today - Join the Fireside Chat with TG's CEO Mike Weiss during the 6th Annual Evercore ISI HealthCONx Conference at 2:10PM ET today. Webcast at: https://lnkd.in/eguXMYM #TGTX #EvercoreISI #FearlessForPatients

#SaveTheDate Join our CEO Mike Weiss for a Fireside Chat during the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29th at 2:10PM ET. Webcast at: https://lnkd.in/eguXMYM #TGTX #EvercoreISI #FearlessForPatients

#Reminder – Don’t miss today’s Fireside chat with TG’s CEO Mike Weiss at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) Conference. Webcast today, Nov. 6th at 3:10PM ET at https://lnkd.in/eC6nRGS #TGTX #GuggenheimSecurities #FearlessForPatients

#DontMissIt – Join the Fireside Chat with TG CEO Mike Weiss at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) Conference. Webcast on Mon., Nov. 6 at 3:10PM ET at https://lnkd.in/eC6nRGS #TGTX #GuggenheimSecurities #FearlessForPatients

Metric
Company Name	Rhizen Pharmaceuticals	Summit Therapeutics
Symbol
MSH ID	COM:RHIZEN	COM:SUMMITTHERAPEUTICS
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Pharmaceuticals	Biotechnology
Country	IN	US
Stage
Employee Count
Website	rhizen.com	summittherapeutics.com
LinkedIn
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:TGTHERAPEUTICS

TG Therapeutics Inc

Last Close

34.55

22/11 21:00

Market Cap

3.17B

Beta: -

Volume Today

2.57M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue